Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

552 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Simultaneous study of five candidate target antigens (CD20, CD22, CD33, CD52, HER2) for antibody-based immunotherapy in B-ALL: a monocentric study of 44 cases.
Chevallier P, Robillard N, Houille G, Ayari S, Guillaume T, Delaunay J, Harousseau JL, Avet-Loiseau H, Mohty M, Garand R. Chevallier P, et al. Among authors: harousseau jl. Leukemia. 2009 Apr;23(4):806-7. doi: 10.1038/leu.2008.303. Epub 2008 Oct 30. Leukemia. 2009. PMID: 18971949 No abstract available.
Rituximab in CD20 positive multiple myeloma.
Moreau P, Voillat L, Benboukher L, Mathiot C, Dumontet C, Robillard N, Hérault O, Garnache F, Garand R, Varoqueaux N, Avet-Loiseau H, Harousseau JL, Bataille R; IFM group. Moreau P, et al. Among authors: harousseau jl. Leukemia. 2007 Apr;21(4):835-6. doi: 10.1038/sj.leu.2404558. Epub 2007 Feb 1. Leukemia. 2007. PMID: 17268523 Clinical Trial. No abstract available.
Influence of NPM1 and FLT3-ITD status on outcome in relapsed/refractory AML patients receiving salvage therapy including gemtuzumab ozogamicin.
Chevallier P, Prebet T, Pigneux A, Hunault M, Delaunay J, Perry F, Lode L, Richebourg S, Blanchet O, Vey N, Ifrah N, Milpied N, Blaise D, Harousseau JL, Mohty M. Chevallier P, et al. Among authors: harousseau jl. Leukemia. 2010 Feb;24(2):467-9. doi: 10.1038/leu.2009.214. Epub 2009 Oct 22. Leukemia. 2010. PMID: 19847200 No abstract available.
Features of Epstein-Barr Virus (EBV) reactivation after reduced intensity conditioning allogeneic hematopoietic stem cell transplantation.
Peric Z, Cahu X, Chevallier P, Brissot E, Malard F, Guillaume T, Delaunay J, Ayari S, Dubruille V, Le Gouill S, Mahe B, Gastinne T, Blin N, Saulquin B, Harousseau JL, Moreau P, Milpied N, Coste-Burel M, Imbert-Marcille BM, Mohty M. Peric Z, et al. Among authors: harousseau jl. Leukemia. 2011 Jun;25(6):932-8. doi: 10.1038/leu.2011.26. Epub 2011 Feb 25. Leukemia. 2011. PMID: 21350556 Clinical Trial.
A new Leukemia Prognostic Scoring System for refractory/relapsed adult acute myelogeneous leukaemia patients: a GOELAMS study.
Chevallier P, Labopin M, Turlure P, Prebet T, Pigneux A, Hunault M, Filanovsky K, Cornillet-Lefebvre P, Luquet I, Lode L, Richebourg S, Blanchet O, Gachard N, Vey N, Ifrah N, Milpied N, Harousseau JL, Bene MC, Mohty M, Delaunay J. Chevallier P, et al. Among authors: harousseau jl. Leukemia. 2011 Jun;25(6):939-44. doi: 10.1038/leu.2011.25. Epub 2011 Feb 18. Leukemia. 2011. PMID: 21331073
Reactive plasmacytoses can mimick plasma cell leukemia: therapeutical implications.
Touzeau C, Pellat-Deceunynck C, Gastinne T, Accard F, Jego G, Avet-Loiseau H, Robillard N, Harousseau JL, Bataille R, Moreau P. Touzeau C, et al. Among authors: harousseau jl. Leuk Lymphoma. 2007 Jan;48(1):207-8. doi: 10.1080/10428190601016159. Leuk Lymphoma. 2007. PMID: 17325872 No abstract available.
552 results